Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gum disease treatment: can a hyaluronic acid gel regrow bone as well as the standard?

NCT ID NCT07339605

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This study tests whether a hyaluronic acid gel can help regrow bone lost to severe gum disease, compared to the standard enamel matrix derivative gel or no gel at all. All treatments use a minimally invasive, non-surgical technique. Sixty adults with advanced periodontitis will be followed for one year to measure bone fill and patient satisfaction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hyaluronic acid gel and enamel matrix derivative
What this could lead to
If successful, this could offer a simpler, less invasive option for regenerating bone lost to gum disease, potentially reducing the need for surgery.
What could go wrong
This is a small, early-stage trial with only 60 participants. The results may not apply to everyone, and the benefits over standard care are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Periodontitis stage III or IV, grade A or B (Tonetti et al., 2017): attachment loss ≥ 5mm, radiographic bone loss extending to to the middle third and beyond, tooth loss ≥4 due to periodontitis, probing depth (PD) ≥ 6mm. * Older adults ≥ 18 years. The number per sex shall be balanced. * Plaque index (PI) \< 1 following initial periodontal therapy and hygiene instructions. * Bleeding on probing (BoP) ≤ 10%. * Only patients with optimal compliance, assessed during etiological therapy, will be selected. * At least a 2-3 wall interproximal bone defect with a radiographically moderate or deep intrabony defect (≥3mm), PD≥ 6mm using a Williams probe on uniradicular teeth or mandibular molars without furcation involvement after non-surgical periodontal treatment. * Vital teeth or teeth with well-performed root canal treatment. * Absence of caries, prosthetic restoration or periapical infection in the tooth to be regenerated. * Absence of systemic pathology. * Negative history of pregnancy. * Signed informed consent. * The participant is willing and able to comply with the necessary visits for the treatments and evaluations scheduled during the clinical study. Exclusion Criteria: * The participant is pregnant, breastfeeding or plans to become pregnant in the next 6 months. * Smoking ≥10 cigarettes/day. * Daily alcohol intake \> 4U. * Chronic illness or reduced mental capacity that may influence compliance with the protocol. * Medications or drugs that alter the patient's healing or with concomitant oral manifestations that, in the opinion of the investigator, could interfere with the assessment of safety or efficacy. * Systemic diseases that may influence treatment such as diabetes mellitus or rheumatoid disease. * Allergies to drug compounds. * Antibiotic intake 3 months prior to the start of the study or systemic condition requiring antibiotic coverage at the time of periodontal treatment. * Periodontal treatment 6 months prior to the start of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alveolar bone loss* / therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clínica Odontológica de la Universidad de Valencia

    RECRUITING

    Valencia, Valencia, 46010, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.